Guedem Nkwenti
Family · Brooklyn, NYNPI 1952814295
Payments from drug & device makers
Across 297 payments — averaging $24.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$4K
- Gilead$2K
- AbbVie$646
- Johnson & Johnson$539
- Janssen Products, LP$160
- Bayer$77
- plus $296 from 7 others
What the payments were for
- Food & beverage$7,08998%
- Education$1602%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 158 | $3,769 |
| Gilead | 74 | $1,762 |
| AbbVie | 27 | $646 |
| Johnson & Johnson | 20 | $539 |
| Janssen Products, LP | 2 | $160 |
| Bayer | 4 | $77 |
| Novo Nordisk | 3 | $75 |
| Exact Sciences | 2 | $58 |
| Renalytix AI, Inc. | 2 | $49 |
| AstraZeneca | 2 | $47 |
| Merck | 1 | $29 |
| Phadia US Inc. | 1 | $20 |
| GSK | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,249 in reported general payments places this provider in the 95th percentile of 8,883 family providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 62 | $284,112 |
| OzempicSemaglutide | 81 | $77,959 |
| DovatoDolutegravir Sodium/Lamivudine | 25 | $70,300 |
| JanuviaSitagliptin Phosphate | 74 | $68,519 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 20 | $67,365 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 13 | $47,748 |
| JanumetSitagliptin Phos/Metformin Hcl | 43 | $41,156 |
| DescovyEmtricitabine/Tenofov Alafenam | 17 | $37,639 |
| FarxigaDapagliflozin Propanediol | 38 | $37,205 |
| JardianceEmpagliflozin | 42 | $35,333 |
| KerendiaFinerenone | 16 | $23,366 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 28 | $13,874 |
| EntrestoSacubitril/Valsartan | 17 | $13,151 |
| TrulicityDulaglutide | 11 | $11,892 |
| Spiriva RespimatTiotropium Bromide | 17 | $8,983 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya, Descovy | $1,762 | $369,49992 claims |
| MerckJanuvia, Janumet | $29 | $109,675117 claims |
| Novo NordiskOzempic | $75 | $77,95981 claims |
| Viiv Healthcare CompanyDovato | $3,769 | $70,30025 claims |
| AstraZenecaFarxiga, Symbicort | $47 | $40,97255 claims |
| BayerKerendia | $77 | $23,36616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,883 family providers in New York.
Other family in Brooklyn
- Seida VelijaBrooklyn$62K
- Ofiong OkonBrooklyn$44K
- Irina FainbergBrooklyn$23K
- Susan WeissBrooklyn$22K
- Razan AlawadhiBrooklyn$21K
- Christina LaoBrooklyn$20K
- Christina NalboneNew York$197K
- Casey GrilloNew York$191K
- Suzanne WilsonIthaca$179K
- Jonathan LesuerSyracuse$172K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.